Please login to the form below

Farxiga

This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.

Boehringer/Lilly's Jardiance hits the mark in pivotal heart failure trial

This includes AstraZeneca’s Farxiga (dapagliflozin), which became the first drug in the SGLT2 inhibitor class to be approved in the US to reduce the chance of hospitalisations, in adults with ... Earlier this week, AZ also touted results for Farxiga in

Latest news

AstraZeneca escapes pandemic impact as new drugs bolster revenues

Over in its CVRM franchise, total revenue reached $2.26bn thanks to strong sales of its heart failure med Farxiga (dapagliflozin) and Brilinta (ticagrelor).
AstraZeneca’s Farxiga scores another FDA fast-track designation

With the FDA designation in hand, AZ will be able to accelerate the research of Farxiga in this patient population. ... As AZ continues to stack up new indications for Farxiga, the drug continues to grow at an exponential rate, bringing in an impressive
Merck, Bayer get FDA priority review for heart failure drug

That includes Novartis’ Entresto (sacubitril/valsartan), which demonstrated 20% overall reduction in deaths or hospitalisations, and AstraZeneca’s Farxiga/Forxiga (dapagliflozin) which had a 26% improvement in cardiovascular death and worsening
Merck, Bayer flesh out vericiguat heart failure data at ACC

Some outstanding questions include where vericiguat lies in relation to the SGLT2 inhibitors such as Boehringer Ingelheim/Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga/Forxiga (dapagliflozin), which are also ... On the face of it,
FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

from AstraZeneca’s Farxiga/Forxiga (dapagliflozin) and Johnson &Johnson’s Invokana (canagliflozin). ... Last July the FDA also turned down AstraZeneca’s filing for Farxiga in type 1 diabetes, although the drug has been approved in this indication

More from news
Approximately 12 fully matching, plus 39 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma companies to watch

Diabetes therapy Farxiga (dapagliflozin) has the potential to go where no other drug in the SGLT2 inhibitor class has gone before as it secures approval for heart failure in both diabetic
China: AstraZeneca’s new engine for growth and innovation

One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.
Transforming times at AstraZeneca

and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months: ...
July 2020: diversity and inclusion in clinical trials round-up: COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020: In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...